Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule.

Autor: Schurink-van 't Klooster TM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. Electronic address: tessa.schurink@rivm.nl., Donken R; Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada.; Women's Health Research Institute, BC Women's Hospital + Health Centre, University of British Colombia, Vancouver, BC, Canada., Schepp RM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., van der Klis FRM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands., de Melker HE; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2018 Nov 26; Vol. 36 (49), pp. 7580-7587. Date of Electronic Publication: 2018 Oct 28.
DOI: 10.1016/j.vaccine.2018.10.018
Abstrakt: Background: In this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination.
Methods: A blood sample at 7, 12 and 24 months after the first dose and questionnaire data were collected (n = 56). HPV type-specific antibody concentrations (lU/ml) against seven types (HPV16/18/31/33/45/52/58) were assessed using a validated virus-like particles (VLP) multiplex immunoassay. Avidity was tested using a modification of this assay.
Results: Seropositivity for vaccine types HPV 16 and 18 was 100% up to month 24, but declined for HPV-types 31/33/45/52/58, although not statistically significant for HPV45. All Geometric Mean Concentrations (GMCs) declined by months 12 and 24, but remained high for HPV16/18. Between month 7 and 12, GMCs declined more for other types. High avidity antibodies were induced up to 24 months for vaccine types (75%, 76-78% and 81-82% at months 7, 12 and 24, respectively), but for other types antibody avidity was 16-29% at month 7, 20-32% at month 12 and 19-32% at month 24.
Conclusions: GMCs declined over time for HPV-types 16/18/31/33/45/52/58, but remained high for vaccine-types HPV16/18 up to 24 months of follow-up. Antibody avidity was >75% for vaccine types but <35% for other HPV-types. Further follow-up of this cohort will provide insight into antibody and avidity kinetics over time.
(Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: